Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
After Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced Thursday that it has crafted a new drug development platform, and created a handful of candidate compounds, shares of the clinical-stage biotech, which is focused on RNAi drug development, rose by 14.7% as of 12:05 p.m. EDT on Friday.
Arrowhead stated that it will be hosting a research and development meeting later Friday where it will provide investors with an overview of its new Targeted RNAi Molecule (TRiM) drug development platform, and sharing a few details about some of its product candidates.
Arrowhead's management team asserts that the TRiM platform will provide the company with several advantages, including:
Source: Fool.com
Arrowhead Pharmaceuticals Inc. Aktie
26,67 €
-0,11 %
Die Community sieht Arrowhead Pharmaceuticals Inc. positiv: Viel mehr Buy- als Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Arrowhead Pharmaceuticals Inc. von 54 € würde den aktuellen Kurs von 26.67 € mehr als verdoppeln.
